• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管内皮生长因子(VEGF)家族中的蛋白水解切割:在促血管生成的VEGF中产生多样性,这对淋巴管生成性VEGF的激活至关重要。

Proteolytic Cleavages in the VEGF Family: Generating Diversity among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs.

作者信息

Künnapuu Jaana, Bokharaie Honey, Jeltsch Michael

机构信息

Drug Research Program, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland.

Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.

出版信息

Biology (Basel). 2021 Feb 23;10(2):167. doi: 10.3390/biology10020167.

DOI:10.3390/biology10020167
PMID:33672235
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7926383/
Abstract

Specific proteolytic cleavages turn on, modify, or turn off the activity of vascular endothelial growth factors (VEGFs). Proteolysis is most prominent among the lymph-angiogenic VEGF-C and VEGF-D, which are synthesized as precursors that need to undergo enzymatic removal of their C- and N-terminal propeptides before they can activate their receptors. At least five different proteases mediate the activating cleavage of VEGF-C: plasmin, ADAMTS3, prostate-specific antigen, cathepsin D, and thrombin. All of these proteases except for ADAMTS3 can also activate VEGF-D. Processing by different proteases results in distinct forms of the "mature" growth factors, which differ in affinity and receptor activation potential. The "default" VEGF-C-activating enzyme ADAMTS3 does not activate VEGF-D, and therefore, VEGF-C and VEGF-D do function in different contexts. VEGF-C itself is also regulated in different contexts by distinct proteases. During embryonic development, ADAMTS3 activates VEGF-C. The other activating proteases are likely important for non-developmental lymphangiogenesis during, e.g., tissue regeneration, inflammation, immune response, and pathological tumor-associated lymphangiogenesis. The better we understand these events at the molecular level, the greater our chances of developing successful therapies targeting VEGF-C and VEGF-D for diseases involving the lymphatics such as lymphedema or cancer.

摘要

特定的蛋白水解切割开启、修饰或关闭血管内皮生长因子(VEGF)的活性。蛋白水解在淋巴管生成相关的VEGF-C和VEGF-D中最为显著,它们以前体形式合成,在激活其受体之前需要经过酶促去除其C端和N端前肽。至少有五种不同的蛋白酶介导VEGF-C的激活切割:纤溶酶、ADAMTS3、前列腺特异性抗原、组织蛋白酶D和凝血酶。除ADAMTS3外,所有这些蛋白酶也能激活VEGF-D。不同蛋白酶的加工产生不同形式的“成熟”生长因子,它们在亲和力和受体激活潜力方面存在差异。“默认”的VEGF-C激活酶ADAMTS3不激活VEGF-D,因此,VEGF-C和VEGF-D在不同情况下发挥作用。VEGF-C本身在不同情况下也受到不同蛋白酶的调节。在胚胎发育过程中,ADAMTS3激活VEGF-C。其他激活蛋白酶可能对非发育性淋巴管生成很重要,例如在组织再生、炎症、免疫反应和病理性肿瘤相关淋巴管生成过程中。我们对这些分子水平事件的理解越深入,就越有机会开发出针对VEGF-C和VEGF-D的成功疗法,用于治疗涉及淋巴管的疾病,如淋巴水肿或癌症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/fe85886c8bde/biology-10-00167-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/19c6a82c45ca/biology-10-00167-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/c595ad23bc6f/biology-10-00167-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/5e453829c84a/biology-10-00167-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/81961bdd7c96/biology-10-00167-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/36f8f97c0d2a/biology-10-00167-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/fe85886c8bde/biology-10-00167-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/19c6a82c45ca/biology-10-00167-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/c595ad23bc6f/biology-10-00167-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/5e453829c84a/biology-10-00167-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/81961bdd7c96/biology-10-00167-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/36f8f97c0d2a/biology-10-00167-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d73/7926383/fe85886c8bde/biology-10-00167-g006.jpg

相似文献

1
Proteolytic Cleavages in the VEGF Family: Generating Diversity among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs.血管内皮生长因子(VEGF)家族中的蛋白水解切割:在促血管生成的VEGF中产生多样性,这对淋巴管生成性VEGF的激活至关重要。
Biology (Basel). 2021 Feb 23;10(2):167. doi: 10.3390/biology10020167.
2
Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1.有效的淋巴管生成生长因子 VEGF-C 的激活需要 VEGF-C 的 C 末端结构域和 CCBE1 的 N 末端结构域。
Sci Rep. 2017 Jul 7;7(1):4916. doi: 10.1038/s41598-017-04982-1.
3
Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.纤溶酶激活淋巴管生成生长因子VEGF-C和VEGF-D。
J Exp Med. 2003 Sep 15;198(6):863-8. doi: 10.1084/jem.20030361. Epub 2003 Sep 8.
4
KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D.KLK3/PSA 和组织蛋白酶 D 激活 VEGF-C 和 VEGF-D。
Elife. 2019 May 17;8:e44478. doi: 10.7554/eLife.44478.
5
CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation.CCBE1 通过 ADAMTS-3 介导的血管内皮生长因子-C 激活增强淋巴管生成。
Circulation. 2014 May 13;129(19):1962-71. doi: 10.1161/CIRCULATIONAHA.113.002779. Epub 2014 Feb 19.
6
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.参与血管生成与淋巴管生成的血管内皮生长因子及其受体。
Curr Opin Cell Biol. 2009 Apr;21(2):154-65. doi: 10.1016/j.ceb.2008.12.012. Epub 2009 Feb 21.
7
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.淋巴管生成生长因子血管内皮生长因子(VEGF)-C和-D的差异受体结合及调控机制
J Biol Chem. 2016 Dec 30;291(53):27265-27278. doi: 10.1074/jbc.M116.736801. Epub 2016 Nov 16.
8
VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.通过腺病毒导入骨骼肌的血管内皮生长因子(VEGF)中,VEGF-D是最强的血管生成和淋巴管生成效应因子。
Circ Res. 2003 May 30;92(10):1098-106. doi: 10.1161/01.RES.0000073584.46059.E3. Epub 2003 Apr 24.
9
Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.血管内皮生长因子-D 受体结合和特异性的结构决定因素。
Blood. 2011 Feb 3;117(5):1507-15. doi: 10.1182/blood-2010-08-301549. Epub 2010 Dec 8.
10
The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.VEGF-D 的前肽决定肝素结合、受体异二聚化以及对肿瘤生物学的影响。
J Biol Chem. 2013 Mar 22;288(12):8176-8186. doi: 10.1074/jbc.M112.439299. Epub 2013 Feb 12.

引用本文的文献

1
Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives.健康与疾病中的血管内皮生长因子信号传导:从分子机制到治疗前景
Signal Transduct Target Ther. 2025 May 19;10(1):170. doi: 10.1038/s41392-025-02249-0.
2
Neutrophils in tumor- and inflammation-induced lymphangiogenesis.肿瘤和炎症诱导的淋巴管生成中的中性粒细胞。
Int J Biol Sci. 2025 Feb 26;21(5):2223-2234. doi: 10.7150/ijbs.103458. eCollection 2025.
3
Beyond vessels: unraveling the impact of VEGFs on neuronal functions and structure.

本文引用的文献

1
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.CRISPR-Cas9 基因编辑治疗镰状细胞病和 β-地中海贫血。
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
2
VEGF-C protects the integrity of the bone marrow perivascular niche in mice.VEGF-C 可保护小鼠骨髓腔周细胞龛的完整性。
Blood. 2020 Oct 15;136(16):1871-1883. doi: 10.1182/blood.2020005699.
3
Phase 1 Lymfactin Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema.
超越血管:揭示血管内皮生长因子对神经元功能和结构的影响
J Biomed Sci. 2025 Mar 6;32(1):33. doi: 10.1186/s12929-025-01128-8.
4
Characterization of hepatocarcinoma cells: lymphatic metastasis potential through enhanced production, expression, and secretion along the VEGF-C/D-VEGFR-3/NRP-2 axis.肝癌细胞的特征:通过沿VEGF-C/D-VEGFR-3/NRP-2轴增强产生、表达和分泌实现淋巴转移潜能
Discov Oncol. 2025 Feb 17;16(1):191. doi: 10.1007/s12672-025-01901-z.
5
Molecular and Cellular Machinery of Lymphatic Metastasis in Breast Cancer.乳腺癌淋巴转移的分子与细胞机制
Onco Targets Ther. 2025 Feb 4;18:199-209. doi: 10.2147/OTT.S503272. eCollection 2025.
6
Insulin Receptor Substrate-2 Regulates the Secretion of Growth Factors in Response to Amino Acid Deprivation.胰岛素受体底物-2调节生长因子在应对氨基酸剥夺时的分泌。
Int J Mol Sci. 2025 Jan 20;26(2):841. doi: 10.3390/ijms26020841.
7
The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases.组织蛋白酶在免疫和炎症反应中的多方面作用:对癌症治疗、自身免疫性疾病和传染病的影响。
Biomark Res. 2024 Dec 31;12(1):165. doi: 10.1186/s40364-024-00711-9.
8
Molecular Characterization and Interaction between Human VEGF-D and VEGFR-3.人血管内皮生长因子-D(VEGF-D)与血管内皮生长因子受体-3(VEGFR-3)之间的分子特征及相互作用
J Microbiol Biotechnol. 2024 Dec 28;34(12):2627-2636. doi: 10.4014/jmb.2409.09060. Epub 2024 Nov 20.
9
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives.肿瘤转移的机制洞察与治疗干预:最新进展与展望
Signal Transduct Target Ther. 2024 Aug 2;9(1):192. doi: 10.1038/s41392-024-01885-2.
10
Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema.阿利匹仑 - VEGF-C mRNA 递呈治疗继发性淋巴水肿。
EMBO Mol Med. 2024 Feb;16(2):386-415. doi: 10.1038/s44321-023-00017-7. Epub 2024 Jan 2.
第一阶段淋巴管生成素研究:联合腺病毒 VEGF-C 和淋巴结转移治疗上肢淋巴水肿的短期安全性。
J Plast Reconstr Aesthet Surg. 2020 Sep;73(9):1612-1621. doi: 10.1016/j.bjps.2020.05.009. Epub 2020 May 18.
4
Specific fibroblast subpopulations and neuronal structures provide local sources of Vegfc-processing components during zebrafish lymphangiogenesis.在斑马鱼淋巴管生成过程中,特定的成纤维细胞亚群和神经元结构为 Vegfc 加工成分提供了局部来源。
Nat Commun. 2020 Jun 1;11(1):2724. doi: 10.1038/s41467-020-16552-7.
5
Update and audit of the St George's classification algorithm of primary lymphatic anomalies: a clinical and molecular approach to diagnosis.原发性淋巴异常的圣乔治分类算法的更新和审核:一种临床和分子诊断方法。
J Med Genet. 2020 Oct;57(10):653-659. doi: 10.1136/jmedgenet-2019-106084. Epub 2020 May 14.
6
Atypical cadherin FAT4 orchestrates lymphatic endothelial cell polarity in response to flow.非典型钙黏蛋白 FAT4 响应流动调控淋巴内皮细胞极性。
J Clin Invest. 2020 Jun 1;130(6):3315-3328. doi: 10.1172/JCI99027.
7
CRISPR treatment inserted directly into the body for first time.CRISPR疗法首次直接注入人体。
Nature. 2020 Mar;579(7798):185. doi: 10.1038/d41586-020-00655-8.
8
Complex formation of anti-VEGF-C with VEGF-C released during blood coagulation resulted in an artifact in its serum pharmacokinetics.抗 VEGF-C 与在血液凝固过程中释放的 VEGF-C 形成复合物,导致其血清药代动力学出现假象。
Pharmacol Res Perspect. 2020 Apr;8(2):e00573. doi: 10.1002/prp2.573.
9
Efficient homing of T cells via afferent lymphatics requires mechanical arrest and integrin-supported chemokine guidance.通过输入淋巴管实现 T 细胞的有效归巢需要机械性停滞和整合素支持的趋化因子引导。
Nat Commun. 2020 Feb 28;11(1):1114. doi: 10.1038/s41467-020-14921-w.
10
VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours.VEGF-C 驱动的淋巴引流使脑肿瘤能够进行免疫监视。
Nature. 2020 Jan;577(7792):689-694. doi: 10.1038/s41586-019-1912-x. Epub 2020 Jan 15.